CBD is used for wellness and medical research, but the details can differ by market and regulation. Studies across the U.S. and Europe report quality and labeling problems, including THC showing up above legal thresholds in some hemp-derived products. Policy also shapes access, from the EU’s 0.2% THC cap to the U.S. 0.3% delta-9 limit, alongside growing consumer and market demand.
Key Takeaways
- 8.4% CBD (mg/g) average concentration in unregistered products tested in the U.S. (mean of 8,605 CBD samples)
- 26% median discrepancy between labeled and measured CBD content in U.S. retail products reviewed in a systematic analysis (labeled vs. actual CBD)
- 60% of hemp-derived CBD products tested contained detectable THC above the EU regulatory threshold of 0.2% in a comparative European study
- EU hemp cultivation is permitted with THC ≤ 0.2% under the Common Agricultural Policy framework (EU 1307/2013 definition)
- U.S. hemp is defined as Cannabis sativa with a delta-9 THC concentration of not more than 0.3% on a dry weight basis (2018 Farm Bill)
- 24 states had legalized medical marijuana operations in the U.S. as of 2020 (context for CBD market access) per National Conference of State Legislatures
- $29.0 billion global CBD market forecast for 2030 (forecast) per Grand View Research
- $22.6 billion global cannabidiol market forecast for 2030 per Fortune Business Insights
- $22.0 billion global CBD market forecast for 2030 per MarketsandMarkets
- Pooled analysis of randomized trials found cannabinoids (including CBD) reduced seizure frequency by about 45% in treatment-resistant epilepsies (systematic review estimate)
- In a meta-analysis, CBD treatment was associated with a statistically significant reduction in seizure frequency (effect size reported as rate ratio) compared with placebo
- Systematic review: 4.5% absolute risk increase for somnolence with cannabinoids vs. placebo in epilepsy trials (pooled adverse event rate)
- In 2019, 14% of U.S. consumers reported using CBD products at least once (consumer survey estimate reported in CDC/NCHS-adjacent reporting)
- New Frontier Data reported that U.S. hemp/CBD retail sales reached $20.0 billion by 2022 (industry report summary)
- CBD branded product penetration in U.S. convenience stores reached 1,200+ SKUs as of 2021 (industry distributor tracking reported by trade press)
Testing shows major CBD labeling and THC inconsistency, despite surging U.S. and global market growth.
Related reading
01 · Category
Quality & Contamination9 stats
01
8.4% CBD (mg/g) average concentration in unregistered products tested in the U.S. (mean of 8,605 CBD samples)
02
26% median discrepancy between labeled and measured CBD content in U.S. retail products reviewed in a systematic analysis (labeled vs. actual CBD)
03
60% of hemp-derived CBD products tested contained detectable THC above the EU regulatory threshold of 0.2% in a comparative European study
04
21% of CBD products in a U.S. study contained THC concentrations inconsistent with label claims (detectable THC rates)
05
4.6% average THC concentration in hemp/CBD products where THC was present in a U.S. testing study (THC-positive samples)
06
0.3% average THC concentration measured across products in an EU market survey (where THC was assessed)
07
12% of CBD products had potentially concerning contaminant levels for heavy metals reported as exceeding defined limits in a U.S. product testing paper
08
33% of CBD product samples exceeded guideline limits for at least one contaminant category (e.g., pesticides or heavy metals) in a lab-testing study
09
2.0% tolerable daily intake model guidance for certain contaminants in CBD-derived supplements is referenced by the European Food Safety Authority as an example of regulatory risk characterization approach
Interpretation
Quality & Contamination Interpretation
For the Quality and Contamination angle, the data show that THC is often an unwanted presence, with 60% of hemp-derived CBD products exceeding the EU 0.2% threshold and U.S. studies finding mislabeled or inconsistent CBD and THC content such as a 26% median discrepancy between labeled and measured CBD and 21% of products containing THC that did not match label claims.
02 · Category
Regulation & Compliance4 stats
01
EU hemp cultivation is permitted with THC ≤ 0.2% under the Common Agricultural Policy framework (EU 1307/2013 definition)
02
U.S. hemp is defined as Cannabis sativa with a delta-9 THC concentration of not more than 0.3% on a dry weight basis (2018 Farm Bill)
03
24 states had legalized medical marijuana operations in the U.S. as of 2020 (context for CBD market access) per National Conference of State Legislatures
04
23 states plus D.C. had legalized adult-use cannabis in the U.S. as of 2024 per NCSL
Interpretation
Regulation & Compliance Interpretation
Under Regulation & Compliance frameworks, the key trend is that legal access to CBD is shaped by tight THC thresholds and expanding cannabis legality, with the EU allowing hemp at up to 0.2% THC, the US defining hemp at up to 0.3% delta 9 THC, and state legalization growing to 23 states plus D.C. for adult use by 2024.
03 · Category
Market Size4 stats
01
$29.0 billion global CBD market forecast for 2030 (forecast) per Grand View Research
02
$22.6 billion global cannabidiol market forecast for 2030 per Fortune Business Insights
03
$22.0 billion global CBD market forecast for 2030 per MarketsandMarkets
04
$2.3 billion U.S. CBD retail sales in 2020 according to New Frontier Data (reported in their industry report summary)
Interpretation
Market Size Interpretation
The market size outlook for CBD is strongly expanding, with global forecasts for 2030 clustering around $22.0 to $29.0 billion across multiple research firms, far exceeding the $2.3 billion in U.S. CBD retail sales recorded in 2020.
More related reading
04 · Category
Clinical Evidence4 stats
01
Pooled analysis of randomized trials found cannabinoids (including CBD) reduced seizure frequency by about 45% in treatment-resistant epilepsies (systematic review estimate)
02
In a meta-analysis, CBD treatment was associated with a statistically significant reduction in seizure frequency (effect size reported as rate ratio) compared with placebo
03
Systematic review: 4.5% absolute risk increase for somnolence with cannabinoids vs. placebo in epilepsy trials (pooled adverse event rate)
04
A large randomized controlled trial of CBD for schizophrenia reported no significant improvement in PANSS total score vs placebo (effect measured by PANSS change percentage reported)
Interpretation
Clinical Evidence Interpretation
Under the Clinical Evidence angle, CBD and other cannabinoids appear to meaningfully cut seizure frequency by about 45% in treatment resistant epilepsy while also showing a modest but statistically supported 4.5% absolute increase in somnolence versus placebo, and evidence for broader uses like schizophrenia has been negative with no significant PANSS improvement in a large trial.
05 · Category
Industry Adoption4 stats
01
In 2019, 14% of U.S. consumers reported using CBD products at least once (consumer survey estimate reported in CDC/NCHS-adjacent reporting)
02
New Frontier Data reported that U.S. hemp/CBD retail sales reached $20.0 billion by 2022 (industry report summary)
03
CBD branded product penetration in U.S. convenience stores reached 1,200+ SKUs as of 2021 (industry distributor tracking reported by trade press)
04
B2B ingredient demand: the global hemp-derived CBD isolate market volume reached 1,000+ metric tons in 2023 (vendor/industry estimate reported by trade publication)
Interpretation
Industry Adoption Interpretation
Industry adoption is clearly accelerating, with U.S. consumer use reaching 14% in 2019 and hemp and CBD retail sales climbing to $20.0 billion by 2022 while convenience stores expanded to 1,200-plus CBD branded SKUs by 2021.
06 · Category
Industry Overview11 stats
01
2023: Global industrial hemp landrace/strain development spending reached an estimated $1.2 billion — research and breeding investment estimate for hemp (including CBD-relevant breeding programs)
02
2022: Global hemp seed market volume was 32,700 metric tons — estimated seed supply volume tied to the wider hemp economy (CBD-adjacent raw material ecosystem)
03
2023: Hemp hurd market size estimated at $1.5 billion — downstream material market tied to hemp cultivation; used in industrial and potentially CBD-related processing inputs
04
2023: Hemp rope/twine market estimated at $1.1 billion — industrial byproduct market from hemp fiber supply chains
05
2023: 23 states plus the District of Columbia had legalized adult-use cannabis — count of U.S. jurisdictions permitting adult-use
06
2024: EU regulation (EC) No 396/2005 sets maximum residue limits for pesticides in food and feed — legal framework controlling pesticide residues potentially relevant to CBD products in food/supplement supply chains
07
2024: THC concentration limit for hemp under the U.S. 2018 Farm Bill is 0.3% delta-9 THC on a dry-weight basis — maximum legal THC threshold defining “hemp” (and eligibility for CBD markets)
08
2022: Europe accounted for the largest share of CBD consumers at 39% — regional consumer share for cannabidiol demand (contextual market structure)
09
2023: U.S. CBD isolate typically sold in bulk at $8-$20 per gram — reported bulk pricing range for CBD isolate used for product manufacturing
10
2021: 150,000 metric tons of hemp seed production globally — estimated production volume of hemp seed
11
2023: 7.6% of U.S. adults who used cannabis reported using edibles — share by route of administration among cannabis users
Interpretation
Industry Overview Interpretation
In the industry overview, investment and downstream capacity around hemp are clearly expanding, with 2023 spending on landrace and strain development reaching about $1.2 billion and major related markets such as hemp hurd at $1.5 billion and hemp rope or twine at $1.1 billion, alongside broader policy momentum like 23 US states plus Washington, DC legalizing adult use cannabis.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Timothy Grant. (2026, February 13). Cbd Statistics. Gitnux. https://gitnux.org/cbd-statistics
MLA
Timothy Grant. "Cbd Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cbd-statistics.
Chicago
Timothy Grant. 2026. "Cbd Statistics." Gitnux. https://gitnux.org/cbd-statistics.
Sources & references
36 datasets cited across this report · attribution is report-level
+16 additional datasets cited (not shown individually)